Related Experiment Videos
Radioimmunology. Imaging and therapy.
1Department of Medical Imaging, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Cancer
|February 15, 1991
Summary
Radioimmunotherapy uses radiolabeled antibodies to target tumors, showing promise in diagnosing and treating cancers like melanoma and lymphoma. Advances in antibody engineering and imaging are enhancing its effectiveness.
Area of Science:
- Oncology
- Immunology
- Radiochemistry
Background:
- Monoclonal antibody development via hybridoma technology has significantly advanced radioimmunologic techniques.
- Over 110 clinical trials demonstrate the evolving role of radiolabeled antibodies in cancer diagnosis and therapy.
Purpose of the Study:
- To review the progress and potential of targeting radioactivity to tumors using antitumor antibodies.
- To highlight key advancements and future directions in radioimmunologic methods for cancer management.
Main Methods:
- Review of clinical trials (1978-present) involving radiolabeled antibodies for various malignancies.
- Analysis of antibody-antigen targeting, radioisotope labeling, and imaging techniques.
Main Results:
- Radiolabeled antibodies have successfully detected occult tumors in melanoma, lymphoma, neuroblastoma, and colorectal cancers.
- Radioimmunotherapy has achieved durable remissions in lymphoma patients refractory to conventional treatments.
- Specific examples like I-131, 3-F8 and In-111 T-101 show consistent tumor targeting.
Conclusions:
- Radioimmunologic methods are transitioning from experimental to practical diagnostic and therapeutic tools for common human cancers.
- Future innovations in genetic engineering (humanized antibodies) and imaging (PET, fusion imaging) promise to enhance tumor localization and treatment efficacy.